News | January 26, 2015

FEops Closes Financing to Commercialize TAVIguide Service

Pre-operative planning service offers improved prediction of device-patient interaction

FEops, TAVIguide, Series A financing, navigation, advanced visualization

Image courtesy of FEops


January 26, 2015 — FEops announced the closing of a €1.3 million (~$1.9 million USD) series A financing round, led by Capricorn Venture Partners and PMV. The funding will be used to support the launch of FEops’ first product, TAVIguide, in key markets in Europe and the United States.

TAVIguide is a cloud based pre-operative planning service for transcatheter aortic valve implantation (TAVI). Part of the proceeds will be dedicated to advance clinical development of the technology and diversify the pre-operative planning services offered to include additional cardiovascular interventions.

Current TAVI planning relies on pre-operative imaging such as echography or computed tomography (CT), but accurate measurements of the pre-operative patient anatomy are insufficient to avoid complications. By combining pre-operative CT imaging with advanced computer simulations, TAVIguide technology can predict how a certain medical device will interact with a specific patient. Based on these insights, the physician gets a better view on the device-patient interaction, prior to the intervention, thus allowing optimal personalized device selection and risk management.

For more information: www.feops.com


Additional Content

News | Heart Valve Technology

Oct. 29, 2026 — Abbott has initiated the CROWN-MV pivotal trial evaluating the safety and effectiveness of its ...

Home November 05, 2026
Home
News | Heart Valve Technology

Oct. 21, 2026 — Edwards Lifesciences Corp. recently announced that the U.S. Food and Drug Administration (FDA) has ...

Home October 23, 2026
Home
News | Heart Valve Technology

Sept. 22, 2026 — Following transcatheter aortic valve implantation (TAVI), disturbances in the heart’s electrical ...

Home September 25, 2026
Home
News | Heart Valve Technology

Sept. 22, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai have received a $3.6 million, four-year ...

Home September 24, 2026
Home
News | Heart Valve Technology

June 29, 2026 — Laplace Interventional recently announced that the U.S. Food and Drug Administration (FDA) has approved ...

Home July 02, 2026
Home
Subscribe Now